Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy

INTRODUCTION: Selective blockade of the integrins and mucosal adhesion molecules is a promising therapeutic strategy for ulcerative colitis (UC). Vedolizumab (VDZ), a humanized IgG1 monoclonal antibody against α4β7 integrin, selectively blocks the trafficking of the leukocytes into the gastrointesti...

Descripción completa

Detalles Bibliográficos
Autores principales: Takatsu, Noritaka, Hisabe, Takashi, Higashi, Daijiro, Ueki, Toshiharu, Matsui, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131995/
https://www.ncbi.nlm.nih.gov/pubmed/32280316
http://dx.doi.org/10.2147/CE.S179053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131995/
https://www.ncbi.nlm.nih.gov/pubmed/32280316
http://dx.doi.org/10.2147/CE.S179053

Ejemplares similares